Inovio Pharmaceuticals share price logo

Inovio Pharmaceuticals

NASDAQ: INO

$1.25

-0.03

(-2.34%)

as on

Inovio Pharmaceuticals Stock Performance

as on September 14, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $1.23
    $1.31
    downward going graph

    1.60%

    Downside

    4.80%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $0.56
    $2.82
    downward going graph

    54.94%

    Downside

    125.60%

    Upside

    downward going graph

Inovio Pharmaceuticals share price movements today

Previous Close
$1.28
Open
$1.29
Volume
3.3M
Market Cap
$147.9M
Day's Low - High
$1.23 - $1.31
52 Week Low - High
$0.56 - $2.82

Inovio Pharmaceuticals Historical Returns

1 Month Return
+ 79.25 %
3 Month Return
+ 21.1 %
1 Year Return
-50 %
3 Year Return
-75.66 %
5 Year Return
-98.62 %

Inovio Pharmaceuticals Stock Fundamentals & Key Indicators

Check Inovio Pharmaceuticals market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$147.9M

EPS (TTM)

-1.1654

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-1.13

Industry PE ratio

-1.62

PEG Ratio

-0.00410588991442914

EBITDA

-64.9M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-1005.80%

Inovio Pharmaceuticals Stock Valuation

Track how Inovio Pharmaceuticals P/E has moved over time to understand its valuation trends.

Inovio Pharmaceuticals in the last 5 years

  • Overview

  • Trends

Lowest (-42.32x)

December 31, 2021

Industry (-1.62x)

December 31, 2025

Today (-0.96x)

December 31, 2025

Highest (-0.46x)

December 31, 2024

LowHigh

Today’s Price to Earnings Ratio: -0.96x

Inovio Pharmaceuticals vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Inovio Pharmaceuticals with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$147.9M-98.62%-1.130.00%NA
BUY$44.6B614.61%NA0.00%NA
BUY$138.4B181.2%30.5486.04%NA
BUY$56.0B-69.82%-16.99-12.57%NA
BUY$85.2B24.16%19.2884.86%45.660000000000004%

Stock Returns calculator for Inovio Pharmaceuticals Stock including INR - Dollar returns

The Inovio Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Inovio Pharmaceuticals investment value today

Current value as on today

₹51,340

Returns

-₹48,660

(-48.66%)

Returns from Inovio Pharmaceuticals Stock

-₹52,652 (-52.65%)

Dollar Impact

₹3,991 (+3.99%)

Analyst Recommendation on Inovio Pharmaceuticals Stock

Based on 3 analysts

BUY

66.67%

Buy

33.33%

Hold

0.00%

Sell

Based on 3 analysts, 66.66666666666666% of analysts recommend a 'BUY' rating for Inovio Pharmaceuticals. Average target price of $3.17

Inovio Pharmaceuticals Share Price Target

Get share price movements and forecasts by analysts on Inovio Pharmaceuticals.

What analysts predicted

60.57%UPSIDE

Target Price

$3.17

Current Price

$1.25

Analyzed by

3 Analysts

Target

$3.17

Inovio Pharmaceuticals target price $3.17, a slight upside of 60.57% compared to current price of $1.25. According to 3 analysts rating.

Indian Investors' Interest in Inovio Pharmaceuticals Stock

Search interest for Inovio Pharmaceuticals Stock has increased by 158% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:158% versus previous 30 day period

Inovio Pharmaceuticals Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
-
0
-
0
0
-
-
-
-
-
Gross Profit
-
0
-
0
0
0
-
0
0
-
Operating Income
-31
-33
-27
-20
-25
-23
-21
-17
-21
-18
EBITDA
-29
-31
-24
-18
-18
-22
-44
4
-18
-5
Interest Expense
0
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-30
-32
-25
-19
-19
-23
-45
3
-19
-6
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-30
-32
-25
-19
-19
-23
-45
3
-19
-6
Net Profit Margin
0.00%
-722.36%
0.00%
-563.14%
100.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Inovio Pharmaceuticals Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
42
30
4
7
1
10
0
0
0
Gross Profit
42
30
4
7
1
10
0
0
0
Operating Income
-83
-94
-111
-124
-301
-267
-143
-112
-86
EBITDA
-84
-89
-107
-149
-296
-270
-130
-103
-81
Interest Expense
0
-
7
8
1
1
1
0
-
Depreciation
3
4
5
4
4
5
3
3
2
Income Before Tax
-88
-94
-120
-167
-303
-279
-135
-107
-84
Income Tax Expense
-
2
0
-
-
-
-
-
-
Net Income
-88
-96
-119
-166
-303
-279
-135
-107
-84
Net Profit Margin
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%

Inovio Pharmaceuticals Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-30
-32
-25
-19
-19
-23
-45
3
-19
-6
Operating Cash Flow
-28
-28
-27
-19
-26
-20
-21
-19
-21
-18
Investing Cash Flow
45
9
14
34
0
5
8
0
2
6
Financing Cash Flow
-11
33
0
29
1
0
24
27
0
17
Change in Cash
5
14
-12
44
-25
-15
12
7
-18
5

Inovio Pharmaceuticals Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-88
-96
-120
-167
-303
-279
-135
-107
-84
Operating Cash Flow
-63
-73
-97
-177
-215
-216
-124
-104
-88
Investing Cash Flow
-27
42
-9
-58
-175
109
87
104
14
Financing Cash Flow
95
31
105
465
211
81
4
51
53
Change in Cash
4
0
-1
228
-179
-24
-32
51
-21

Mutual Funds that own Inovio Pharmaceuticals Stock

Check out the Mutual Funds with significant holdings in Inovio Pharmaceuticals.

Funds
Holdings
Shares Held
Fidelity Securities Fund
8.176966%
8454780
VANGUARD INDEX FUNDS
2.727775%
2820452
Fidelity Concord Street Trust
0.570269%
589644
Bridgeway Funds, Inc.
0.167315%
173000
VANGUARD INSTITUTIONAL INDEX FUNDS
0.040636%
42017

Global Institutional Holdings in Inovio Pharmaceuticals

Funds
Holdings
Vanguard
3.45%
iShares
0.27%
Thomas E. Claugus
0.12%
Invesco
0.08%

Insights on Inovio Pharmaceuticals

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -19.68M → -6.01M (in $), with an average increase of 227.4% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 512.4% return, outperforming this stock by 559.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 27.6% return, outperforming this stock by 103.5%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 3 quarters, 116.99K → -65.34K (in $), with an average decrease of 122.1% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, INO stock has moved down by -12.6%

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company's partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
OrganisationInovio Pharmaceuticals
Headquarters660 West Germantown Pike, Plymouth Meeting, PA, United States, 19462
IndustryBiotechnology
CEODr. Jacqueline E. Shea Ph.D.
E-voting on sharesClick here to vote

Key Management of Inovio Pharmaceuticals

Name

Title

Mr. Shawn D. Bridy M.A., M.B.A.

Senior Vice President of Business Development

Dr. Jacqueline E. Shea Ph.D.

CEO, President & Director

Dr. Laurent M. Humeau Ph.D.

Chief Scientific Officer & Chairman of the Scientific Advisory Board

Dr. Jeffrey Skolnik M.D.

Senior Vice President of Clinical Development

Mr. Robert J. Juba Jr.

Senior Vice President of Biological Manufacturing & Clinical Supply Management

Mr. E. J. Brandreth MBA

Senior Vice President of Quality Assurance

Mr. Peter D. Kies

Chief Financial Officer

Dr. Michael Sumner B.S., M.B.A., M.D.

Chief Medical Officer & Head of Development

Mr. Robert L. Crotty J.D.

General Counsel, Corporate Secretary & Chief Compliance Officer

Ms. Jennie Willson

Director of Communications

FAQs

What is Inovio Pharmaceuticals share price today?

Inovio Pharmaceuticals share price today is $1.25 as on at the close of the market. Inovio Pharmaceuticals share today touched a day high of $1.31 and a low of $1.23.

What is the 52 week high and 52 week low for Inovio Pharmaceuticals share?

Inovio Pharmaceuticals share touched a 52 week high of $2.82 on and a 52 week low of $0.56 on . Inovio Pharmaceuticals stock price today i.e. is closed at $1.25,which is 55.67% down from its 52 week high and 121.95% up from its 52 week low.

What is Inovio Pharmaceuticals's market capitalisation today?

Inovio Pharmaceuticals market capitalisation is $0.00T as on .

How to invest in Inovio Pharmaceuticals Stock (INO) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Inovio Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Inovio Pharmaceuticals Shares that will get you 1.2000 shares as per Inovio Pharmaceuticals share price of $1.25 per share as on September 14, 2026 at 8:46 am IST.

What is the minimum amount required to buy Inovio Pharmaceuticals Stock (INO) from India?

Indian investors can start investing in Inovio Pharmaceuticals (INO) shares with as little as ₹95.55 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹955.50 in Inovio Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on ). Based on Inovio Pharmaceuticals share’s latest price of $1.25 as on September 14, 2026 at 8:46 am IST, you will get 8.0000 shares of Inovio Pharmaceuticals. Learn more about fractional shares .

What are the returns that Inovio Pharmaceuticals has given to Indian investors in the last 5 years?

Inovio Pharmaceuticals stock has given -98.62% share price returns and 29.74% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?